AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Pediatric Dermatology for the Adult Dermatologist

Description

In a session focused on pediatric dermatology aimed at adult dermatologists, moderator Steve Humphrey, an associate professor at the Medical College of Wisconsin, discusses the unique aspects of treating pediatric patients. He highlights that children are not merely small adults; they present with different dermatological conditions and require specialized knowledge. Key topics include the differences in skin disorders, particularly atopic dermatitis, and the limited access pediatric patients have to specialized care. The session covers the unique diagnostic testing challenges in children, the fewer medications approved for their use, and the problems encountered in treatment due to children's distinct physiological responses. Additionally, the conversation engages with the importance of mental health and quality of life impacts on pediatric patients suffering from skin conditions. The roadmap for the session includes discussions on pediatric skin disorders, management strategies, and treatment options, particularly highlighting aspects such as the diagnostic criteria for melanoma in children and systemic therapy preparations like methotrexate, cyclosporine, and various biologics for severe cases of atopic dermatitis. Emphasis is placed on the importance of quality of life in affected children and their families, including the financial and emotional impacts of chronic dermatological conditions.

View more

Conclusions

  • Pediatric dermatology is distinct from adult dermatology due to differences in skin conditions.
  • Access to pediatric dermatology care is severely limited, particularly in rural areas, with only 317 pediatric dermatologists in the U.S. as of 2020.
  • The approach to diagnosing and treating skin disorders in children must account for unique challenges such as pain during testing and limited medication approval for their age group.
  • Diagnostic techniques and medications often need adjustment due to a child's smaller body surface area and varying tolerance to treatments.
  • Pediatric patients with skin conditions are frequently under-treated, which can lead to complications such as chronic infections and a negative impact on quality of life.
  • Atopic dermatitis presents differently in children than in adults, necessitating tailored treatment strategies.
  • Systemic medications should be considered when topical treatments are insufficient, with careful assessment of each child's needs and quality of life.
  • Quality of life is significantly affected by skin conditions in children, influencing their academic performance and family dynamics.
  • Recent advancements have introduced new therapies for atopic dermatitis in pediatric patients, yet careful treatment planning and patient education remain vital.
  • Roberts M et al. Pediatr Dermatol. 2021 Nov;38 Suppl 2:106-109
  • Cordoro KM et al. J Am Acad Dermatol. 2013 Jun;68(6):913-25
  • Ashrafzadeh S et al. Pediatr Dermatol. 2020 Nov;37(6):1098-1105
  • Lyon et al. Pediatr Dermatol. 2008 Jan-Feb;25(1):109-11
  • Tam et al. Curr Allergy Asthma Rep. 2020 Jun 16;20(9):41
  • Sun HY et al. Pediatr Dermatol. 2022 Jan;39(1):42-48
  • Ramírez-Marín HA, Silverberg JI. Differences between pediatric and adult atopic dermatitis. Pediatr Dermatol. 2022; 39: 345-353.
  • Simpson, E. L., et al. (2017). When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. JAAD, 77(4), 623-633.
  • Sidbury R et al. J Am Acad Dermatol. 2014 Dec;71(6):1218-33. doi: 10.1016/j.jaad.2014.08.038. Epub 2014 Sep 26. PMID: 25264237; PMCID: PMC4430554.
  • Paller AS, Flohr C, Cork M, et al. Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial. JAMA Dermatol. 2023;159(6):596-605. doi:10.1001/jamadermatol.2023.062
  • Eichenfield LF, Flohr C, Sidbury R, et al. Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial. JAMA Dermatol. 2021;157(10):1165-1173.
  • Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, Werfel T, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021 Jun 5;397(10290):2169-2181. doi: 10.1016/S0140-6736(21)00589-4. Epub 2021 May 21. Erratum in: Lancet. 2021 Jun 19;397(10292):2336. Erratum in: Lancet. 2021 Aug 28;3